ABSTRACT:

The prognosis for pancreatic cancer (PC) is poor making it a substantial treatment challenge. A potentially effective treatment option is immunotherapy. To better understand the changing field of immunotherapy in PC management, this analysis will focus on important tactics and their consequences. To find relevant research published between 2019 and 2024, a thorough literature search was carried out using Scopus, Google Scholar, and PubMed. Tumor cells may be targeted and immune responses can be modulated using passive immunotherapeutic techniques such as CAR T-cell therapy and programmed death checkpoint inhibitors. Preclinical and clinical studies show enhanced effectiveness of combination therapy, such as anti-PD-1/anti-PD-L1 plus CTLA-4 inhibitors. Although their efficacy varies, active immunotherapeutic strategies, in particular cancer vaccines, seek to promote immune recognition of tumor antigens. Subpar response rates and treatment-related toxicity are obstacles. Checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines are a few possible therapeutic options in the exciting field of immunotherapy for PC treatment. Nevertheless, further study is required to enhance these strategies and enhance patient.

KEYWORDS:

Immunotherapy, pancreatic cancer 

REFERENCES :

1) Rangelova E, Kaipe H. Immunotherapy in pancreatic cancer – an emerging role: a narrative review. Chinese Clin Oncol [Internet]. 2022 Feb 1 [cited 2024 Mar 17];11(1):4–4. Available from: https://cco.amegroups.org/article/view/90353/html
2) Verbeke CS, Leitch D, Menon K V., McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006 Oct;93(10):1232–7.
3) Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012 Jan 20;148(1–2):349–61.
4) Johnson JI, Decker S, Zaharevitz D, Rubinstein L V., Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001 May 18;84(10):1424–31.
5) Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012 Aug 15;18(16):4266–76.
6) Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (80- ). 2009 Jun 12;324(5933):1457–61.
7) Buchanan T, Amouzegar A, Luke JJ. Next-Generation Immunotherapy Approaches in Melanoma. Curr Oncol Rep. 2021 Oct 1;23(10).
8) Robert C, Schachter J, Long G V., Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521–32.
9) Brower V. Checkpoint blockade immunotherapy for cancer comes of age. J Natl Cancer Inst. 2015 Mar 1;107(3).
10) Ott PA, Bang YJ, Piha-Paul SA, Abdul Razak AR, Bennouna J, Soria JC, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019 Feb 1;37(4):318–27.
11) O’Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab with or Without Tremelimumab for Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 1;5(10):1431–8.
12) Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 2018 Mar 28;8(MAR).
13) Ji H huan, Tang X wen, Dong Z, Song L, Jia Y tao. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clin Drug Investig. 2019 Mar 4;39(3):319–30.
14) Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther [Internet]. 2021 Feb 1 [cited 2024 Mar 17];53(3):374–82. Available from: https://pubmed.ncbi.nlm.nih.gov/33314269/
15) Mcdonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol. 2015 Jan 1;45(1):49–59.
16) Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, et al. Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. Am J Cancer Res [Internet]. 2021 [cited 2024 Mar 17];11(7):3445. Available from: /pmc/articles/PMC8332864/
17) Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, et al. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer. 2020 Nov 13;8(2).
18) Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, et al. Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma (Investigational New Drugs, (2018), 36, 1, (96-102), 10.1007/s10637-017-0525-1). Invest New Drugs. 2019 Aug 15;37(4):797.
19) Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022 Dec 1;15(1).
20) McCarthy PM, Rendo MJ, Uy MD, Adams AM, O’Shea AE, Nelson DW, et al. Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma. Onco Targets Ther. 2021;14:3537–44.
21) Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692–7.
22) Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A, et al. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2020 May 1;25(5):e808–15.
23) Huber M, Brehm CU, Gress TM, Buchholz M, Alhamwe BA, von Strandmann EP, et al. The immune microenvironment in pancreatic cancer. Int J Mol Sci. 2020 Oct 1;21(19):1–33.
24) Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. 2018 Jul 1;155(1):29–32.
25) Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014 Jun 1;74(11):2907–12.
26) Beatty GL, Haas AR, Maus M V., Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 Feb 1;2(2):112–20.
27) Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Jun 1;618(7963):144–50.
28) Palmer DH, Valle JW, Ting Ma Y, Faluyi O, Neoptolemos JP, Jensen Gjertsen T, et al. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. Br J Cancer. 2020 Mar 31;122(7):971–7.
29) Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, et al. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. J Pancreat Cancer. 2021 Mar 1;7(1):8–19.
30) Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019 Sep 15;25(18):5493–502.
31) Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun 1;24(6):1150–8.
32) Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, et al. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 May 30;11(1).
33) Lim SH, Yun J, Lee MY, Kim HJ, Kim KH, Kim SH, et al. Gemcitabine and Erlotinib with or without Oxaliplatin in previously untreated advanced pancreatic cancer: A randomized phase ii trial. Yonsei Med J. 2021 Aug 1;62(8):671–8.
34) Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, et al. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist. 2019 May 1;24(5):589-e160.
35) Mettu NB, Niedzwiecki D, Rushing C, Nixon AB, Jia J, Haley S, et al. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Cancer Chemother Pharmacol. 2019 Jun 1;83(6):1025–35.
36) Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, et al. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results. Eur J Cancer. 2020 Oct 1;138:172–81.
37) Wei AC, Ou FS, Shi Q, Carrero X, O’Reilly EM, Meyerhardt J, et al. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec 1;26(13):4489–97.
38) Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 May 1;32(5):600–8.
39) Bendell J, Sharma S, Patel MR, Windsor KS, Wainberg ZA, Gordon M, et al. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. Oncologist. 2020 Nov 1;25(11):954–62.
40) Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O’Neil BH, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun 1;38(3):821–30.

‏